Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02497001 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
A Phase 3 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,902
- Enrollment target
NCT02497001 is a Phase 3 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 1,902 participants.
The verdict
NCT02497001, a Phase 3 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,902 participants
- Enrollment target
Study Summary
Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.
Interventions
- DRUG BGF MDI 320/14.4/9.6 μg
- DRUG BFF MDI (PT009) 320/9.6 μg
- DRUG GFF MDI (PT003) 14.4/9.6 μg
- DRUG Symbicort® Turbuhaler® (TBH) Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,902 participants |
| Start Date | 2015-08-10 |
| Est. Completion | 2018-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02497001
The ClinicalTrials.gov registry entry for NCT02497001 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,902 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pearl Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BGF MDI 320/14.4/9.6 μg is the first listed.
NCT02497001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02497001 about?
NCT02497001 is a clinical study titled "A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)". Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.
What is the current status of trial NCT02497001?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,902 participants. The study started on 2015-08-10. Estimated completion is 2018-01-05.
What interventions are being tested in trial NCT02497001?
The interventions under investigation include: BGF MDI 320/14.4/9.6 μg (DRUG), BFF MDI (PT009) 320/9.6 μg (DRUG), GFF MDI (PT003) 14.4/9.6 μg (DRUG), Symbicort® Turbuhaler® (TBH) Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT02497001?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.